Can Topical Peptides Repigment Hypopigmented Scars?
Hypopigmentation, or localized loss of color, is a frequent and challenging complication following burn injuries and hypertrophic scar development. While research into melanogenesis pathways has shown how peptides can signal melanin synthesis, getting topically applied compounds past the tough skin barrier remains a fundamental hurdle. In a 2023 laboratory investigation published in Lasers in Surgery and Medicine, scientists explored whether combining laser technology with synthetic peptide solutions could activate pigment production in scars.
Why Is Hypopigmentation in Burn Scars Difficult to Manage?
Hypertrophic scar (HTS) tissue that forms after a burn injury frequently presents with dyschromia, displaying mixed patches of hyperpigmentation and hypopigmentation. Available medical therapies for these color irregularities remain limited. According to research in Lasers in Surgery and Medicine, prior laboratory work demonstrated that hypopigmented scars completely lack expression of alpha melanocyte stimulating hormone (α-MSH). However, when melanocytes from these hypopigmented tissues were exposed to synthetic α-MSH in cell cultures (in vitro), they retained the cellular capacity to repigment. This finding led researchers to examine whether a similar repigmentation response could be stimulated in living tissue (in vivo).
How Was Laser-Assisted Drug Delivery Tested?
To overcome the challenge of moving large peptide molecules into dense scar tissue, researchers evaluated laser-assisted drug delivery (LADD). The preclinical investigation used a red Duroc pig model with established hypertrophic scars. At Day 77 (designated as the pre-treatment baseline), scars underwent fractional ablative laser treatment (FLSR) using a carbon dioxide (CO2) laser to create microscopic treatment zones.
The study protocol evaluated two specific groups:
- Active treatment group (n = 6): Scars received CO2 laser conditioning followed by a topical solution of synthetic α-MSH (NDP α-MSH) dissolved in l-tyrosine.
- Control group (n = 2): Scars underwent identical laser therapy but received laser-assisted delivery of l-tyrosine alone, without the synthetic peptide.
Treatments and examinations occurred weekly through Week 4. To track tissue changes, the investigators gathered digital images along with punch biopsies from hyperpigmented, hypopigmented, and normally pigmented scar and uninjured skin tissue.
What Did Image Analysis Reveal About Pigment Spread?
Pre-treatment baseline measurements showed that the surface areas of hyperpigmentation varied significantly across scars before any intervention began. To account for these initial differences, researchers normalized each scar to its own pre-treatment value, presenting the results as fold-change. Digital photographs were analyzed using ImageJ software by tracing the visible regions of pigmentation.
Within the treated scars receiving synthetic α-MSH and l-tyrosine, the pigmented area expanded gradually each week, reaching a 1.3-fold increase over baseline by Week 4. When evaluating the treated group against the control group receiving l-tyrosine alone across all timepoints, the treated scars demonstrated consistently higher fold-changes in pigmented area:
- Week 1: 1.04 ± 0.05 in treated scars vs. 0.89 ± 0.08 in control scars
- Week 2: 1.21 ± 0.07 in treated scars vs. 0.98 ± 0.24 in control scars
- Week 3: 1.21 ± 0.08 in treated scars vs. 1.04 ± 0.11 in control scars
- Week 4: 1.28 ± 0.11 in treated scars vs. 0.94 ± 0.25 in control scars
How Did Melanogenesis Genes Respond to Treatment?
To evaluate biological activity within the tissue, investigators separated epidermal sheets from punch biopsies using dispase, extracted RNA, and ran quantitative real-time PCR (qRT-PCR). They measured three primary melanogenesis-related genes: tyrosinase (TYR), tyrosinase-related protein-1 (TYRP1), and dopachrome tautomerase (DCT).
Before treatment, hypopigmented scars showed profound suppression of these genes compared to normal skin:
- Tyrosinase (TYR): Baseline levels were -17.76 ± 4.52 below normal skin. Following the first laser session, TYR dropped further to -43.49 ± 5.52, a dip the authors noted was potentially caused by laser fractionation. After 2, 3, and 4 treatments, expression steadily climbed back (-35.74 ± 15.72 at Week 2, -23.25 ± 6.80 at Week 3), reaching -5.52 ± 2.22 by Week 4 (p < 0.01), approaching normal skin levels.
- TYRP1: Expression dropped from a baseline of -12.94 ± 1.82 down to -48.85 ± 13.25 after Week 1 (p < 0.01). With continued weekly sessions, levels rose through Weeks 2, 3, and 4 (-34.45 ± 14.64, -28.19 ± 4.98, and -6.93 ± 3.05; p < 0.01 at Week 4).
- DCT: Expression began at -214.95 ± 89.42, decreased to -487.93 ± 126.32 at Week 1 (p < 0.05), and then recovered during Weeks 2, 3, and 4 (-219.06 ± 79.33, -72.91 ± 20.45 [p < 0.001], and -76.00 ± 24.26 [p < 0.001]).
Similar gene expression patterns occurred in scars receiving laser delivery of l-tyrosine alone. Across all three genes, levels in hyperpigmented scar tissue increased significantly by Week 4 compared to Week 1 (p < 0.01).
What Are the Clinical Limitations of This Research?
While the authors of the 2023 study in Lasers in Surgery and Medicine concluded that fractional ablative laser delivery can be combined with synthetic α-MSH and l-tyrosine to increase pigmentation area and gene expression, the research has clear boundaries. This was a single preclinical study conducted exclusively in a porcine burn model. The study evaluated only 6 treated scars and 2 controls over a brief 4-week window. The authors specifically noted that future studies remain necessary to optimize delivery methods, timing, and dosing.
These findings describe early experimental work on post-burn scar remodeling, not cosmetic tanning. Anyone dealing with patchy skin discoloration, scar hypopigmentation, or pigment loss should always consult a board-certified dermatologist for evidence-based clinical evaluation rather than attempting unapproved experimental peptide approaches.
Sources
Published October 30, 2026. Sources are linked in the text. See our Medical Disclaimer.